Venus Remedies Ltd

Venus Remedies Other Announcement

Venus Remedies relayed social media posts about a SEBI special window for re-lodging physical share transfer requests. The notice carries no monetary event.

Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY

Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.

Key figure

Net profit ₹25.6 Cr · +27.4% YoY

Venus Remedies Regulatory Approval

Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.

Venus Remedies Board Meeting Date

Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.

Venus Remedies Other Announcement

Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.

Venus Remedies Other Announcement

Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.

Venus Remedies Other Announcement

Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.

Venus Remedies Management Change

Venus Remedies Ltd announced the appointment and re-appointment of several Directors, including Executive and Independent Directors, following approval at its 37th Annual General Meeting.

Venus Remedies Annual General Meeting

Venus Remedies Ltd held its 37th Annual General Meeting on August 20, 2026, via video conferencing. The meeting addressed ordinary and special resolutions regarding company business.

Venus Remedies Other Announcement

Venus Remedies informed the exchanges about their social media communications regarding a special window for re-lodgement of physical share transfer requests.

Venus Remedies Annual General Meeting

Venus Remedies Ltd announced its 37th Annual General Meeting scheduled for August 20, 2026, to consider financial statements, dividends, and director re-appointments.

Venus Remedies Q1 FY27 Results: Net Profit ₹23 Cr, Up 139.6% YoY

Venus Remedies Ltd reported revenue from operations of ₹178.9 Cr (+30.4% YoY) and net profit of ₹23 Cr (+139.6% YoY) for Q1 FY27.

Key figure

Net profit ₹23 Cr · +139.6% YoY

Venus Remedies Board Meeting Date

Venus Remedies will hold a board meeting on July 20, 2026. The board will consider and approve unaudited financial results for the June quarter.

Venus Remedies Other Announcement

Venus Remedies secured the renewal of its DSIR in-house R&D recognition for its research center. The certification supports ongoing development of novel antimicrobial resistance treatments.

Venus Remedies Management Change

Venus Remedies appointed Saransh Chaudhary and Gurminder Singh Bedi to its Board. It also re-appointed Manu Chaudhary and Savita Gupta, strengthening leadership for five-year terms.

Venus Remedies Board Meeting Outcome

Venus Remedies approved several board appointments, including Saransh Chaudhary as Executive Director. These leadership changes aim to strengthen governance and strategic oversight for five-year terms.

Venus Remedies Dividend

Venus Remedies recommended a ₹10 final dividend for the financial year 2025-26. The record date is August 7, 2026, with payment expected by September 18.

Venus Remedies Q4 FY26 Results: Net Profit ₹47.5 Cr, Up 126.2% YoY

Venus Remedies Ltd reported revenue from operations of ₹259.4 Cr (+31.2% YoY) and net profit of ₹47.5 Cr (+126.2% YoY) for Q4 FY26.

Key figure

Net profit ₹47.5 Cr · +126.2% YoY

Venus Remedies Financial Results

Venus Remedies reported annual consolidated total income of ₹782.18 Crore and net profit of ₹102.78 Crore. The board recommended a 100% final dividend of ₹10 per share.

Value

₹782.2 Cr

Venus Remedies Regulatory Approval

Venus Remedies received Saudi FDA approval for Plerixafor, its first global oncology marketing authorization. This grants direct access to the GCC's largest pharmaceutical market.

Venus Remedies Other Announcement

Venus Remedies shared social media links to encourage shareholders to update KYC details. This routine compliance effort ensures regulatory alignment and investor records accuracy.

Venus Remedies Other Announcement

Venus Remedies Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by P. Chadha and Associates, confirms the company's compliance with SEBI regulations and listing requirements, with no material deviations or observations reported.

Venus Remedies Business Update

Venus Remedies Limited has disclosed links to social media posts regarding a special window for the re-lodgement of physical share transfer requests. This action follows SEBI guidelines to assist shareholders in converting physical holdings.

Venus Remedies Q3 FY26 Results: Net Profit ₹25.6 Cr, Up 30.6% YoY

Venus Remedies Ltd reported net profit of ₹25.6 Cr (+30.6% YoY) for Q3 FY26.

Key figure

Net profit ₹25.6 Cr · +30.6% YoY

Venus Remedies Other Announcement

Venus Remedies Ltd has issued a social media notice regarding a special window for shareholders to re-lodge transfer requests for physical shares. This follows SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026. The announcement is a regulatory compliance update aimed at assisting shareholders with physical shareholding transitions.

Venus Remedies Other Announcement

Venus Remedies Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The filing, issued by registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and listed within prescribed timelines. This is a routine regulatory disclosure for investors.

Venus Remedies Other Announcement

Venus Remedies Limited's promoters and promoter group have submitted their annual disclosure under SEBI SAST Regulations for the financial year ended March 31, 2026. The promoters declared that no equity shares were encumbered or pledged during the period, providing transparency regarding the stability of promoter shareholding.